MRZM · Marizyme, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $32.9K | - | $181.5K | $184.7K | $129.0K | - | $76.0K | $61.8K |
| Cost of Revenue | - | - | $9.6K | - | $51.0K | $49.6K | $39.3K | - | - | - |
| Gross Profit | - | - | $23.2K | - | $130.5K | $135.1K | $89.7K | - | - | - |
| R&D | $344.1K | $312.3K | $321.9K | - | $492.2K | $691.4K | $606.0K | - | $241.7K | $1.37M |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $1.36M | $1.59M | $1.40M | - | $4.99M | $4.94M | $2.22M | - | $2.31M | $4.66M |
| D&A | $108.8K | $121.3K | $108.8K | - | $210.3K | $210.4K | $210.3K | - | $210.4K | - |
| Operating Income | ($1.36M) | ($1.59M) | ($1.37M) | - | ($4.86M) | ($4.80M) | ($2.13M) | - | ($2.23M) | ($4.60M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.96M) | ($4.07M) | ($6.23M) | - | ($32.45M) | ($20.58M) | ($2.55M) | - | ($1.55M) | ($6.92M) |
| EPS - Basic | ($0.01) | ($0.03) | ($0.05) | - | ($0.71) | ($0.48) | ($0.06) | - | ($0.04) | ($0.17) |
| EPS - Diluted | ($0.01) | ($0.03) | ($0.05) | - | ($0.71) | ($0.17) | - | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.7K | $5.2K | $6.1K | $148.5K | $474.9K | $205.2K | $329.8K | $510.9K | $1.18M | $2.04M |
| Accounts Receivable | $2.0K | - | - | $60.3K | $43.2K | $73.0K | $78.2K | $87.8K | $54.2K | $53.1K |
| Inventory | $26.9K | $26.9K | $15.2K | $24.9K | $99.0K | $139.7K | $176.5K | $215.6K | $251.2K | $268.4K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $854.6K | $922.1K | $735.0K | $968.8K | $1.31M | $1.06M | $1.88M | $1.96M | $2.34M | $2.61M |
| Total Assets | $21.26M | $21.53M | $21.57M | $22.02M | $36.92M | $36.98M | $38.27M | $38.69M | $63.73M | $64.30M |
| Current Liabilities | $29.98M | $23.55M | $25.85M | $20.60M | $48.67M | $20.82M | $8.03M | $2.92M | $1.61M | $1.50M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $36.80M | $30.91M | $32.40M | $26.68M | $58.87M | $29.71M | $23.04M | $21.27M | $22.78M | $22.95M |
| Stockholders' Equity | ($15.54M) | ($9.38M) | ($10.83M) | ($4.66M) | ($21.95M) | $7.27M | $15.23M | $17.42M | $40.95M | $41.35M |
| Retained Earnings | ($170.32M) | ($161.64M) | ($157.56M) | ($151.34M) | ($141.57M) | ($109.12M) | ($88.54M) | ($85.99M) | ($62.43M) | ($60.87M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($809.0K) | - | - | - | ($1.12M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $666.6K | - | - | - | $939.1K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | 70.6% | - | 71.9% | 73.1% | 69.5% | - | - | - |
| Operating margin | - | - | -4176.2% | - | -2675.6% | -2600.4% | -1653.7% | - | -2937.7% | -7445.1% |
| EBITDA margin | - | - | -3845.1% | - | -2559.8% | -2486.5% | -1490.6% | - | -2661.0% | - |
| Net margin | - | - | -18950.8% | - | -17875.5% | -11138.1% | -1980.7% | - | -2042.6% | -11202.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 979.7% | - | 271.2% | 374.3% | 469.9% | - | 318.0% | 2218.9% |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.2% | -18.9% | -28.9% | - | -87.9% | -55.6% | -6.7% | - | -2.4% | -10.8% |
| Return on equity | 12.6% | 43.4% | 57.5% | - | 147.8% | -283.0% | -16.8% | - | -3.8% | -16.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.03 | 0.04 | 0.03 | 0.05 | 0.03 | 0.05 | 0.23 | 0.67 | 1.46 | 1.74 |
| Quick ratio | 0.03 | 0.04 | 0.03 | 0.05 | 0.02 | 0.04 | 0.21 | 0.60 | 1.30 | 1.56 |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.04 | 0.17 | 0.74 | 1.36 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.37 | -2.30 | -1.99 | -4.72 | -1.68 | 5.09 | 2.51 | 2.22 | 1.56 | 1.56 |
| Liabilities / Assets | 1.73 | 1.44 | 1.50 | 1.21 | 1.59 | 0.80 | 0.60 | 0.55 | 0.36 | 0.36 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | 0.63 | - | 0.51 | 0.36 | 0.22 | - | - | - |
| Days sales outstanding | - | - | - | - | 87d | 144d | 221d | - | 260d | 313d |
| Days inventory outstanding | - | - | 575d | - | 709d | 1028d | 1641d | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | 0.5x | - | - | - | - |
| P / S | - | - | 354.7x | - | 55.5x | 18.7x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -74.5% | - | 138.8% | 198.9% | - | - | -39.2% | -61.6% |
| Revenue CAGR (3y) | - | - | -23.7% | - | 13.2% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | 219.9% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | -74.1% | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 72.1% | 66.9% | 35.7% | - | -117.5% | -4.4% | 46.6% | - | -27.2% | -958.1% |
| Net income growth (YoY) | 94.0% | 80.2% | -143.7% | - | -1990.0% | -197.2% | 58.3% | - | 4.9% | -181.4% |
| EPS growth (YoY) | 98.6% | 82.4% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 29.2% | - | - | - | - | -82.4% | -66.3% | -63.5% | 1.8% | 2.0% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing MARIZYME against the 5 most active filers in the same SIC group.